Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion – NSCLC, metastatic

4178 - Entrectinib in Locally Advanced/Metastatic ROS1 and NTRK Fusion-Positive Non-Small Cell Lung Cancer (NSCLC): Updated Integrated Analysis of STARTRK-2, STARTRK-1 and ALKA-372-001


29 Sep 2019


Poster Discussion – NSCLC, metastatic


Filippo Guglielmo De Braud


Annals of Oncology (2019) 30 (suppl_5): v602-v660. 10.1093/annonc/mdz260


F.G.M. De Braud1, S. Siena2, F. Barlesi3, A. Drilon4, B.P. Simmons5, X. Huang5, C. Ye5, R.C. Doebele6

Author affiliations

  • 1 Department Of Medical Oncology And Hematology, Fondazione Irccs Istituto Nazionale Dei Tumori And Department Of Oncology And Hemato-oncology, Università degli Studi di Milano, 20122 - Milan/IT
  • 2 Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda And Department Of Oncology And Hemato-oncology, Università degli Studi di Milano, Milan/IT
  • 3 Aix Marseille University, Assistance Publique-Hôpitaux de Marseille, Marseille/FR
  • 4 Thoracic Oncology Service, Division Of Solid Tumor Oncology, Department Of Medicine, Memorial Sloan Kettering Cancer Center, New York/US
  • 5 ., Genentech, South San Francisco/US
  • 6 Thoracic Oncology Research Initiative, University of Colorado, Aurora/US


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 4178


Entrectinib is a systemic and central nervous system (CNS)-active potent inhibitor of ROS1 and TRKA/B/C. Primary data showed that entrectinib was tolerable and achieved high objective response rates (ORR) in patients (pts) with ROS1-positive (ROS1+), ROS1 inhibitor-naïve NSCLC, and in pts with NTRK fusion-positive (NTRK+) NSCLC, including pts with baseline CNS disease. We present data from an additional 5 months of follow-up.


Pts with locally advanced/metastatic ROS1+ or NTRK+ tumours (with or without baseline CNS disease) confirmed by nucleic acid-based methods, enrolled in global phase I/II entrectinib trials (ALKA-372-001 [EudraCT 2012-000148-88], STARTRK-1 [NCT02097810], STARTRK-2 [NCT02568267]) were included. Disease burden was assessed per blinded independent central review (BICR) using RECIST v1.1, after cycle 1 (4 wks) then every 8 wks. Primary endpoints were ORR and duration of response (DOR) by BICR. Secondary endpoints included ORR and DOR in pts with or without baseline CNS disease, and safety. Intracranial (IC) ORR and DOR were evaluated in pts with baseline CNS disease.


There were 53 efficacy-evaluable pts with treatment-naïve, ROS1+ NSCLC and 10 pts with NTRK+ NSCLC. As of 30 Oct 2018 (additional 5 months’ follow-up), BICR ORR: ROS1+ 79.2% (95% CI 65.9–89.2) and NTRK+ 70.0% (95% CI 34.75–93.33) with complete responses in 5 (9.4%) pts and 1 (10.0%) pt, respectively. In ROS1+ NSCLC, median DOR: 24.6 mo (95% CI 12.6–34.8); in pts with and without baseline CNS disease, ORR was 73.9% (95% CI 51.6–89.8) and 83.3% (95% CI 65.3–94.4); IC ORR was 55.0% (95% CI 31.5–76.9); and median IC DOR was 12.9 mo (95% CI 5.6–not estimable). Additional efficacy for NTRK+ NSCLC pts will be presented. Entrectinib was well tolerated with a safety profile consistent with that previously reported; there were no new or unexpected safety findings.


In line with the primary data, in pts with ROS1+ and NTRK+ NSCLC after an additional 5 months of follow-up, entrectinib was well tolerated and showed clinically meaningful, durable systemic and intracranial responses.

Clinical trial identification

ALKA-372-001 [EudraCT 2012-000148-88] STARTRK-1 [NCT02097810] STARTRK-2 [NCT02568267].

Editorial acknowledgement

Laura Vergoz and Charlotte Kennerley, PhD of Gardiner-Caldwell Communications; funded by F. Hoffmann-La Roche.

Legal entity responsible for the study

F. Hoffmanm-La Roche.


F. Hoffmann-La Roche.


F.G.M. De Braud: Advisory / Consultancy, Officer / Board of Directors: TizianaLife Sciences, BMS, Celgene, Novartis, Servier, Pharm Research Associated, Daiichi Sankyo, Ignyta, Amgen, Pfizer, Octimet Oncology, Incyte, Teofarma, Pierre Fabre, Roche, EMD Serono ; Honoraria (self), Speaker Bureau / Expert testimony, Speaker honoraria: BMS, Eli Lilly, Roche, Amgen, AstraZeneca, Gentili, Fondazione Menarini, Novartis, MSD, Ignyta, Bayer, Noema S.r.l., ACCMED, Dephaforum S.r.l., Nadirex, Roche, Biotechspert Ltd, PriME Oncology, Pfizer . S. Siena: Advisory / Consultancy: Amgen, Bayer, BMS, CheckmAb, Celgene, Daiichi-Sankyo, Incyte, Merck, Novartis, Roche-Genentech, Seattle Genetics. F. Barlesi: Research grant / Funding (institution), Institutional financial interests: AbbVie, ACEA, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer–Ingelheim, Eisai, Eli Lilly Oncology, F. Hoffmann–La Roche Ltd, Genentech, Ipsen, Ignyta, Innate Pharma, Loxo, Novartis, MedImmune, Merck, MSD, Pierre Fabre, Pfizer, Sanofi-Aventis; Honoraria (self), Personal financial interests: AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer–Ingelheim, Eli Lilly Oncology, F. Hoffmann–La Roche Ltd, Novartis, Merck, MSD, Pierre Fabre, Pfizer, Takeda; Non-remunerated activity/ies: Principal Investigator for AstraZeneca, BMS, Merck, Pierre Fabre and Roche sponsored trials (or ISR). A. Drilon: Honoraria (self), Advisory / Consultancy: Ignyta/Genentech/Roche, Loxo/Bayer/Lilly, Takeda/Ariad/Millenium, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Helsinn, Beigene, BergenBio, Hengrui Therapeutics, Exelixis, Tyra Biosciences, Verastem, MORE Health; Research grant / Funding (institution): Pfizer, Exelixis, GlaxoSmithKline, Teva, Taiho, PharmaMar; Research grant / Funding (self): Foundation Medicine; Licensing / Royalties: Wolters Kluwer; Non-remunerated activity/ies, Food/Beverages: Merck, Puma ; Honoraria (self), CME honoraria: Medscape, OncLive, PeerVoice, Physicians Education Resources, Targeted Oncology, Research to Practice. B.P. Simmons: Shareholder / Stockholder / Stock options: Roche (Genentech). X. Huang: Shareholder / Stockholder / Stock options, Full / Part-time employment: Genentech. C. Ye: Full / Part-time employment: Genentech. R.C. Doebele: Advisory / Consultancy: Pfizer, Trovagene, Ariad, Takeda, AstraZeneca, Genentech/Roche, Ignyta, Loxo, Rain; Advisory / Consultancy, Shareholder / Stockholder / Stock options, Chair of Scientific Advisory Board : Rain Therapeutics; Research grant / Funding (self), Research grant / Funding (institution): Ignyta, Loxo, Mirati; Licensing / Royalties: Abbott Molecular, Rain Therapeutics, GVKbio, Chugai, Loxo, Ignyta, Genentech, Ariad, Foundation Medicine, Black Diamond; Honoraria (self): Guardant.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.